EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection. According to the World Health Organization (WHO), an estimated 130–150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015).

In the 9MM, GlobalData epidemiologists forecast that the anti-HCV+ total prevalent cases will increase from 19,842,780 total prevalent cases in 2015 to 20,886,113 total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.53%. China will have the highest number of anti-HCV+ total prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ total prevalent cases. In the 9MM, GlobalData epidemiologists forecast that the HCV RNA+ total prevalent cases will increase from 9,932,624 total prevalent cases in 2015, to 10,399,601 total prevalent cases in 2025, at an AGR of 0.47%. In the 9MM, GlobalData epidemiologists forecast that the anti-HCV+ diagnosed prevalent cases will increase from 5,681,205 diagnosed prevalent cases in 2015, to 5,944,944 diagnosed prevalent cases in 2025, at an AGR of 0.46%. In the 9MM, GlobalData epidemiologists forecast that the HCV RNA+ diagnosed prevalent cases will increase from 2,992,433 diagnosed prevalent cases in 2015, to 3,115,901 diagnosed prevalent cases in 2025, at an AGR of 0.41%.

This forecast is supported by historical data from government reports and national studies published in peer-reviewed journals. All data used for the analysis were country-specific. All studies that were used confirmed anti-HCV+ and HCV RNA+ total prevalent cases through laboratory diagnostic tests. Also, GlobalData epidemiologists did not include studies that oversampled the high-risk population groups, such as IDUs, as we believe this would inflate the anti-HCV+ total prevalence. Furthermore, additional segmentation of the anti-HCV+ diagnosed prevalent cases by age, sex, and liver cirrhosis status will provide the most refined and granular forecast results. The forecast methodology was also consistent across the 9MM, thereby allowing for a meaningful comparison of the forecast numbers in these markets.

Scope

The Hepatitis C Virus (HCV) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of HCV in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the anti-HCV+ and HCV RNA+ total prevalent cases (including diagnosed and undiagnosed), which are segmented by sex and age. The anti-HCV+ total prevalent cases are further segmented by genotype, human immunodeficiency virus (HIV) comorbidity, and hepatitis B virus (HBV) comorbidity among the 9MM. Additionally, the report also includes anti-HCV+ and HCV RNA+ diagnosed prevalent cases, which are also segmented by sex and age. The anti-HCV+ diagnosed prevalent cases are segmented by liver cirrhosis status. The HCV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 Diagnosed Incidence and Total Prevalence

2.3.2 Genotype

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast of HCV (2015–2025)

2.5.1 Total Prevalent Cases

2.5.2 Diagnosed Prevalent Cases

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Physicians and Specialists Included in this Study

3.3 About the Authors

3.3.1 Epidemiologists

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.4 About GlobalData

3.5 About EpiCast

3.6 Contact Us

3.7 Disclaimer

Table

Table 1: Risk Factors and Comorbidities Associated with HCV Infection

Table 2: 9MM, Anti-HCV+ Total Prevalence from 1988–2015

Table 3: Hepatitis C Virus Genotype Description

Table 4: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases

Table 5: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases

Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes

Table 7: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases

Table 8: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases

Table 9: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases

Table 10: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases

Table 11: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status

Table 12: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases

Table 13: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 14. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015

Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 16: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015

Table 17: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 18. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015

Table 19: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 20: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 21: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015

Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 23: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 24: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015

Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 26: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016

Figures

Figure 1: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 2: 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N, 2015

Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, by Sex, N, 2015

Figure 4: 9MM, Age-Standardized Anti-HCV+ Total Prevalence, All Ages, by Sex, %, 2015

Figure 5: 9MM, HIV and HBV Co-Infections Among Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, 2015

Figure 6: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years, 2015–2025

Figure 7: 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N, 2015

Figure 8: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, N, 2015

Figure 9: 9MM, Age-Standardized HCV RNA+ Total Prevalence, All Ages, by Sex, %, 2015

Figure 10: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 11: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N, 2015

Figure 12: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015

Figure 13: 9MM, Age-Standardized Anti-HCV+ Diagnosed Prevalence, All Ages, by Sex, %, 2015

Figure 14: 9MM, Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status, All Ages, Both Sexes, N, 2015

Figure 15: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 16: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N, 2015

Figure 17: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015

Figure 18: 9MM, Age-Standardized HCV RNA+ Diagnosed Prevalence, All Ages, by Sex, %, 2015

Frequently asked questions

EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.